Biopharma company Lonza to lay off 60

Beginning Dec. 1, biopharmaceutical company Lonza will lay off 60 people at its manufacturing plant in Maryland, according to a Maryland WARN notice.

Lonza is a leading supplier to the pharmaceutical, biotech and specialty ingredients markets.

The layoffs are a result of a companywide realignment as the it builds four cell and gene therapy centers in the U.S., the Netherlands and Singapore, a company spokesperson told BioPharma Dive.  

The Maryland plant will shift its focus from cell therapy production to bioscience solutions.

The layoffs are expected to occur over a one-year period.

More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump's plan to lower prescription drug prices: 7 takeaways

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers